Table 1: List of IC50 values obtained from each model used.
The analysis was carried out using the Combenefit 2.021 software allowing to calculate the IC50 values for each drug tested on the models analyzed. Cell models (cell lines and patient-derived 3D tumor organoids), types of assays, drugs and time points are reported. n.d. indicates that the goodness of fit value is too low or a standard Hill equation does not correctly account for the specific agent used. In some cases, the expected interpolated IC50 value has been reported.
| Model used | Drug | Time (hours) | IC50 (∝M) | Assay |
|---|---|---|---|---|
| CH12F3+/+/Δ | Compound #3 | 48 | 1.44 | CellTiter |
| CH12F3Δ/Δ/Δ | 1.9 | |||
| HCT-116 p53+/+ | 0.58 | MTS | ||
| HCT-116 p53−/− | 0.69 | |||
| HCT-116 p53+/+ | 1.04 | RealTime-Glo | ||
| HCT-116 p53−/− | 1.50 | |||
| CH12F3+/+/Δ | APX2009 | 6.61 | CellTiter | |
| CH12F3Δ/Δ/Δ | 9.64 | |||
| HCT-116 p53+/+ | 11.7 | MTS | ||
| HCT-116 p53−/− | 11.6 | |||
| HCT-116 p53+/+ | 10.0 | RealTime-Glo | ||
| HCT-116 p53−/− | 6.39 | |||
| HCT-116 p53+/+ | Fiduxosin | 16.1 | MTS | |
| HCT-116 p53−/− | 15.6 | |||
| HCT-116 p53+/+ | SB206553 | n.d. (>100) | ||
| HCT-116 p53−/− | n.d. (>100) | |||
| HCT-116 p53+/+ | Spiclomazine | 30.4 | ||
| HCT-116 p53−/− | 31.2 | |||
| HCT-116 p53+/+ | MMS | 8 | 721 | |
| HCT-116 p53−/− | 938 | |||
| HCT-116 p53+/+ | Compound #3 | 40 + 8 | 0.373 | |
| HCT-116 p53−/− | 0.58 | |||
| tumor organoid P12 | Compound #3 | 48 | 1.36 | RealTime-Glo |
| tumor organoid P14 | 2.8 | |||
| tumor organoid P16 | 0.71 |